Tariffs take a toll on Philips earnings and profits

Despite meeting first-quarter revenue expectations and surpassing earnings forecasts, the Dutch medical technology giant Philips warned that new tariffs would severely hurt its profitability this year, which caused its shares to drop more than 4% on Tuesday May 6th.

Tariffs take a toll on Philips earnings and profits

Philips’ quarterly revenue of $4.7 billion was in line with analysts’ forecasts. At $0.28 per share, adjusted earnings exceeded the $0.25 consensus estimate, which was a stronger result than anticipated. But the modest financial performance was soon overshadowed by worries about growing trade barriers. The company’s 2025 profit forecast was lowered by CEO Roy Jakobs. He cited an expected $280 million to $340 million hit from recently imposed tariffs. Instead of the previously anticipated range of 11.8% to 12.3%, Philips now anticipates an annual profit margin between 10.8% and 11.3%.

“The newly announced tariffs are having a clear impact,” Jakobs said recently. “While strong demand has allowed us to maintain our sales forecast, we have factored the expected tariff costs into our profit and cash outlook.”

Under President Trump’s revised trade strategy, Philips and other medical device manufacturers have not been exempt from tariffs. These taxes, which have been in place since April 2, have presented additional difficulties for a sector already dealing with supply shortages following the pandemic. Reciprocal tariffs between the U.S. and China, a significant market for Philips, currently include a 125% tax on American exports and a 145% duty on Chinese imports.

Jakobs attempting to reduce trade tension

In an effort to reduce trade tensions, Philips is still interacting with Chinese and American officials, Jakobs underlined. The business is speeding up its efforts to localize its supply chains in key areas in the interim. Since the COVID-19 pandemic, Philips has been reducing its exposure to global disruptions by investing in regional manufacturing capabilities.

“The global medical technology supply chain is inherently complex. It’s not feasible to source all components from a single region,” Jakobs said. “That’s why we’re expanding operations within each of our key markets—Europe, the U.S., and Asia.”

Philips currently runs 46 locations across the US, and it just revealed a new cardiac device facility in Minnesota. In order to counteract tariff pressures, Jakobs said the company is implementing stringent cost controls to prevent raising prices for consumers. Securing a tariff exemption could offer significant relief, as medical devices account for 80% of Philips’ portfolio. Philips is concentrated on enhancing operational resilience and sustaining demand through supply chain agility, though, until trade conditions improve.

Featured Image Credit: Stephen Andrews; Pexels: Thank You!

The post Tariffs take a toll on Philips earnings and profits appeared first on Due.